Skip to content
  • General
  • Business
  • Education
  • Sports
  • Politics
  • Medical
  • Press Releases
Menu
  • General
  • Business
  • Education
  • Sports
  • Politics
  • Medical
  • Press Releases
  • General
  • Business
  • Education
  • Sports
  • Politics
  • Medical
  • Press Releases
Menu
  • General
  • Business
  • Education
  • Sports
  • Politics
  • Medical
  • Press Releases
Search
Close this search box.

November 17, 2026

SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid Leukemia

November 17, 2026

– REGAL trial met its primary endpoint with GPS demonstrating statistically significant and clinically meaningful reduction in risk of death by 41% with median overall survival of 24.0 months versus 14.7 months for best available treatment, and a hazard ratio of 0.59 (p=0.035) – – Company plans to meet with the U.S. Food and Drug […]

Read More

Latest post

Gavi Support Boosts Gambia’s Efforts to Reach Every Child with Vaccines

September 11, 2026

World Health Organization Launches Regional Health Data Hub to Enhance Decision-Making in Africa

September 7, 2026

MSF Provides Emergency Aid to Migrants Rescued from Atlantic Migration Route

September 7, 2026

Liverpool’s Pursuit of Yankuba Minteh Blocked by Brighton, Future Move Possible Says Hurzeler

September 4, 2026

Categories

  • General
  • Business
  • Education
  • Sports
  • Politics
  • Medical
  • Press Releases
  • General
  • Business
  • Education
  • Sports
  • Politics
  • Medical
  • Press Releases
  • Home
  • About Us
  • Contact Us
  • Sitemap
  • Home
  • About Us
  • Contact Us
  • Sitemap
Copyright © 2026 Gambia News Gazette. All RIght Reserved